<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:57:37 -0700</creation_date>
  <update_date>2013-05-27 11:08:01 -0600</update_date>
  <accession>HMDBP01561</accession>
  <secondary_accessions>
    <accession>6857</accession>
    <accession>HMDBP05044</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>Aromatase</synonym>
    <synonym>CYPXIX</synonym>
    <synonym>Cytochrome P-450AROM</synonym>
    <synonym>Estrogen synthase</synonym>
  </synonyms>
  <gene_name>CYP19A1</gene_name>
  <general_function>Involved in monooxygenase activity</general_function>
  <specific_function>Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
</specific_function>
  <pathways>
    <pathway>
      <name>Steroid hormone biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00140</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00053</accession>
      <name>Androstenedione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03955</accession>
      <name>19-Hydroxyandrost-4-ene-3,17-dione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03818</accession>
      <name>5-Androstenediol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03178</accession>
      <name>Heme</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00234</accession>
      <name>Testosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02835</accession>
      <name>Danazol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00142</accession>
      <name>Formic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00145</accession>
      <name>Estrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00151</accession>
      <name>Estradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00217</accession>
      <name>NADP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00221</accession>
      <name>NADPH</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00673</accession>
      <name>Linoleic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01043</accession>
      <name>Arachidonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01355</accession>
      <name>Parathion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01426</accession>
      <name>Formaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01847</accession>
      <name>Caffeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01852</accession>
      <name>All-trans-retinoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01860</accession>
      <name>Paraxanthine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01877</accession>
      <name>Valproic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02190</accession>
      <name>5,6-Epoxy-8,11,14-eicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02232</accession>
      <name>8,9-Epoxyeicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02833</accession>
      <name>Testosterone sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03276</accession>
      <name>Hydrogen sulfide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03956</accession>
      <name>7a-Hydroxytestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03959</accession>
      <name>19-Oxotestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04081</accession>
      <name>6-Hydroxymelatonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04244</accession>
      <name>15(S)-HPETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04264</accession>
      <name>14,15-Epoxy-5,8,11-eicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04673</accession>
      <name>11,12-Epoxyeicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04680</accession>
      <name>16(R)-HETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04684</accession>
      <name>11,12,15-THETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04693</accession>
      <name>11H-14,15-EETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04694</accession>
      <name>11,14,15-THETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04701</accession>
      <name>9,10-Epoxyoctadecenoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04702</accession>
      <name>12,13-EpOME</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04995</accession>
      <name>Codeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05038</accession>
      <name>Citalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05050</accession>
      <name>15H-11,12-EETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06768</accession>
      <name>19-Oxoandrost-4-ene-3,17-dione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06769</accession>
      <name>19-Hydroxytestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11136</accession>
      <name>19(S)-HETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14400</accession>
      <name>Diethylstilbestrol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14414</accession>
      <name>Chlorotrianisene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14437</accession>
      <name>Etomidate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14477</accession>
      <name>Methadone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14501</accession>
      <name>Aminoglutethimide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14502</accession>
      <name>Mefloquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14511</accession>
      <name>Levonorgestrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14533</accession>
      <name>Carbimazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14586</accession>
      <name>Betamethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14624</accession>
      <name>Raloxifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13866</accession>
      <name>N-Desmethyltamoxifen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14994</accession>
      <name>Chlorphenesin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14995</accession>
      <name>Terbinafine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14996</accession>
      <name>Drostanolone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15020</accession>
      <name>Clomifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15031</accession>
      <name>Testolactone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15109</accession>
      <name>Edetic Acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15119</accession>
      <name>Nandrolone phenpropionate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15125</accession>
      <name>Exemestane</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15141</accession>
      <name>Letrozole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15142</accession>
      <name>Tioconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01389</accession>
      <name>Melatonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15242</accession>
      <name>Miconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15259</accession>
      <name>Econazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15348</accession>
      <name>Anastrozole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15358</accession>
      <name>Levomethadyl Acetate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15360</accession>
      <name>Paclitaxel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15364</accession>
      <name>Dexamethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15583</accession>
      <name>Bifonazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15587</accession>
      <name>Cyproterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01897</accession>
      <name>Substance P</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15619</accession>
      <name>Sulfathiazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15655</accession>
      <name>Methyltestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15694</accession>
      <name>Nandrolone decanoate</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>heme binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>electron carrier activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>iron ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>monooxygenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>dendritic spine</description>
      <go_id>GO:0043197</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id>GO:0005789</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>neuronal cell body</description>
      <go_id>GO:0043025</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>synaptic vesicle</description>
      <go_id>GO:0008021</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>terminal button</description>
      <go_id>GO:0043195</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>aromatase activity</description>
      <go_id>GO:0070330</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>electron carrier activity</description>
      <go_id>GO:0009055</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>heme binding</description>
      <go_id>GO:0020037</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>iron ion binding</description>
      <go_id>GO:0005506</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>oxygen binding</description>
      <go_id>GO:0019825</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>adrenal gland development</description>
      <go_id>GO:0030325</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>androgen metabolic process</description>
      <go_id>GO:0008209</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>bile acid metabolic process</description>
      <go_id>GO:0008206</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>biphenyl metabolic process</description>
      <go_id>GO:0018879</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>bone development</description>
      <go_id>GO:0060348</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to fibroblast growth factor stimulus</description>
      <go_id>GO:0044344</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to follicle-stimulating hormone stimulus</description>
      <go_id>GO:0071372</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to glucose stimulus</description>
      <go_id>GO:0071333</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular response to hydrostatic pressure</description>
      <go_id>GO:0071464</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dibenzo-p-dioxin metabolic process</description>
      <go_id>GO:0018894</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>estrogen biosynthetic process</description>
      <go_id>GO:0006703</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>granulocyte differentiation</description>
      <go_id>GO:0030851</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>hippocampus development</description>
      <go_id>GO:0021766</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>hypothalamus development</description>
      <go_id>GO:0021854</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>male gonad development</description>
      <go_id>GO:0008584</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>melatonin metabolic process</description>
      <go_id>GO:0030186</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>phthalate metabolic process</description>
      <go_id>GO:0018963</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>progesterone metabolic process</description>
      <go_id>GO:0042448</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>prostate gland growth</description>
      <go_id>GO:0060736</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of synapse structure and activity</description>
      <go_id>GO:0050803</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to cesium ion</description>
      <go_id>GO:0010164</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to estradiol stimulus</description>
      <go_id>GO:0032355</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to herbicide</description>
      <go_id>GO:0009635</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to ionizing radiation</description>
      <go_id>GO:0010212</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to morphine</description>
      <go_id>GO:0043278</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to testosterone stimulus</description>
      <go_id>GO:0033574</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xenobiotic metabolic process</description>
      <go_id>GO:0006805</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Peripheral membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>15</chromosome_location>
    <locus>15q21.1</locus>
    <gene_sequence>&gt;1512 bp
ATGGTTTTGGAAATGCTGAACCCGATACATTATAACATCACCAGCATCGTGCCTGAAGCC
ATGCCTGCTGCCACCATGCCAGTCCTGCTCCTCACTGGCCTTTTTCTCTTGGTGTGGAAT
TATGAGGGCACATCCTCAATACCAGGTCCTGGCTACTGCATGGGAATTGGACCCCTCATC
TCCCACGGCAGATTCCTGTGGATGGGGATCGGCAGTGCCTGCAACTACTACAACCGGGTA
TATGGAGAATTCATGCGAGTCTGGATCTCTGGAGAGGAAACACTCATTATCAGCAAGTCC
TCAAGTATGTTCCACATAATGAAGCACAATCATTACAGCTCTCGATTCGGCAGCAAACTT
GGGCTGCAGTGCATCGGTATGCATGAGAAAGGCATCATATTTAACAACAATCCAGAGCTC
TGGAAAACAACTCGACCCTTCTTTATGAAAGCTCTGTCAGGCCCCGGCCTTGTTCGTATG
GTCACAGTCTGTGCTGAATCCCTCAAAACACATCTGGACAGGTTGGAGGAGGTGACCAAT
GAATCGGGCTATGTGGACGTGTTGACCCTTCTGCGTCGTGTCATGCTGGACACCTCTAAC
ACGCTCTTCTTGAGGATCCCTTTGGACGAAAGTGCTATCGTGGTTAAAATCCAAGGTTAT
TTTGATGCATGGCAAGCTCTCCTCATCAAACCAGACATCTTCTTTAAGATTTCTTGGCTA
TACAAAAAGTATGAGAAGTCTGTCAAGGATTTGAAAGATGCCATAGAAGTTCTGATAGCA
GAAAAAAGACGCAGGATTTCCACAGAAGAGAAACTGGAAGAATGTATGGACTTTGCCACT
GAGTTGATTTTAGCAGAGAAACGTGGTGACCTGACAAGAGAGAATGTGAACCAGTGCATA
TTGGAAATGCTGATCGCAGCTCCTGACACCATGTCTGTCTCTTTGTTCTTCATGCTATTT
CTCATTGCAAAGCACCCTAATGTTGAAGAGGCAATAATAAAGGAAATCCAGACTGTTATT
GGTGAGAGAGACATAAAGATTGATGATATACAAAAATTAAAAGTGATGGAAAACTTCATT
TATGAGAGCATGCGGTACCAGCCTGTCGTGGACTTGGTCATGCGCAAAGCCTTAGAAGAT
GATGTAATCGATGGCTACCCAGTGAAAAAGGGGACAAACATTATCCTGAATATTGGAAGG
ATGCACAGACTCGAGTTTTTCCCCAAACCCAATGAATTTACTCTTGAAAATTTTGCAAAG
AATGTTCCTTATAGGTACTTTCAGCCATTTGGCTTTGGGCCCCGTGGCTGTGCAGGAAAG
TACATCGCCATGGTGATGATGAAAGCCATCCTCGTTACACTTCTGAGACGATTCCACGTG
AAGACATTGCAAGGACAGTGTGTTGAGAGCATACAGAAGATACACGACTTGTCCTTGCAC
CCAGATGAGACTAAAAACATGCTGGAAATGATCTTTACCCCAAGAAACTCAGACAGGTGT
CTGGAACACTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>503</residue_number>
    <molecular_weight>57882.48</molecular_weight>
    <theoretical_pi>7.502</theoretical_pi>
    <pfams>
      <pfam>
        <name>p450</name>
        <pfam_id>PF00067</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Cytochrome P450 19A1
MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLI
SHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKL
GLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTN
ESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWL
YKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCI
LEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFI
YESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAK
NVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLH
PDETKNMLEMIFTPRNSDRCLEH</protein_sequence>
  </protein_properties>
  <genbank_protein_id>61354153</genbank_protein_id>
  <uniprot_id>P11511</uniprot_id>
  <uniprot_name>CP19A_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1TQA</pdb_id>
    <pdb_id>3EQM</pdb_id>
    <pdb_id>3S79</pdb_id>
    <pdb_id>3S7S</pdb_id>
    <pdb_id>4GL5</pdb_id>
    <pdb_id>4GL7</pdb_id>
  </pdb_ids>
  <genbank_gene_id>AY957953</genbank_gene_id>
  <genecard_id>CYP19A1</genecard_id>
  <geneatlas_id>CYP19A1</geneatlas_id>
  <hgnc_id>HGNC:2594</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Harada N: Cloning of a complete cDNA encoding human aromatase: immunochemical identification and sequence analysis. Biochem Biophys Res Commun. 1988 Oct 31;156(2):725-32.</reference_text>
      <pubmed_id>2973313</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen SA, Besman MJ, Sparkes RS, Zollman S, Klisak I, Mohandas T, Hall PF, Shively JE: Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA. 1988 Jan-Feb;7(1):27-38.</reference_text>
      <pubmed_id>3390233</pubmed_id>
    </reference>
    <reference>
      <reference_text>Corbin CJ, Graham-Lorence S, McPhaul M, Mason JI, Mendelson CR, Simpson ER: Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. Proc Natl Acad Sci U S A. 1988 Dec;85(23):8948-52.</reference_text>
      <pubmed_id>2848247</pubmed_id>
    </reference>
    <reference>
      <reference_text>Toda K, Terashima M, Mitsuuchi Y, Yamasaki Y, Yokoyama Y, Nojima S, Ushiro H, Maeda T, Yamamoto Y, Sagara Y, et al.: Alternative usage of different poly(A) addition signals for two major species of mRNA encoding human aromatase P-450. FEBS Lett. 1989 Apr 24;247(2):371-6.</reference_text>
      <pubmed_id>2541021</pubmed_id>
    </reference>
    <reference>
      <reference_text>Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, Mendelson CR, Simpson ER: Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol Chem. 1989 Nov 15;264(32):19385-91.</reference_text>
      <pubmed_id>2808431</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pompon D, Liu RY, Besman MJ, Wang PL, Shively JE, Chen S: Expression of human placental aromatase in Saccharomyces cerevisiae.  Mol Endocrinol. 1989 Sep;3(9):1477-87.</reference_text>
      <pubmed_id>2691883</pubmed_id>
    </reference>
    <reference>
      <reference_text>Harada N, Ogawa H, Shozu M, Yamada K, Suhara K, Nishida E, Takagi Y: Biochemical and molecular genetic analyses on placental aromatase (P-450AROM) deficiency. J Biol Chem. 1992 Mar 5;267(7):4781-5.</reference_text>
      <pubmed_id>1371509</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Evans CT, Ledesma DB, Schulz TZ, Simpson ER, Mendelson CR: Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6387-91.</reference_text>
      <pubmed_id>3018730</pubmed_id>
    </reference>
    <reference>
      <reference_text>Simpson ER, Evans CT, Corbin CJ, Powell FE, Ledesma DB, Mendelson CR: Sequencing of cDNA inserts encoding aromatase cytochrome P-450 (P-450AROM). Mol Cell Endocrinol. 1987 Aug;52(3):267-72.</reference_text>
      <pubmed_id>3653507</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mahendroo MS, Means GD, Mendelson CR, Simpson ER: Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. J Biol Chem. 1991 Jun 15;266(17):11276-81.</reference_text>
      <pubmed_id>2040633</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mahendroo MS, Mendelson CR, Simpson ER: Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J Biol Chem. 1993 Sep 15;268(26):19463-70.</reference_text>
      <pubmed_id>7690033</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen S, Shively JE, Nakajin S, Shinoda M, Hall PF: Amino terminal sequence analysis of human placenta aromatase.  Biochem Biophys Res Commun. 1986 Mar 28;135(3):713-9.</reference_text>
      <pubmed_id>3964273</pubmed_id>
    </reference>
    <reference>
      <reference_text>Honda S, Harada N, Takagi Y: Novel exon 1 of the aromatase gene specific for aromatase transcripts in human brain. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1153-60.</reference_text>
      <pubmed_id>8117272</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP: A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol. 2006 Oct;24(10):1285-92. Epub 2006 Sep 10.</reference_text>
      <pubmed_id>16964243</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ghosh D, Griswold J, Erman M, Pangborn W: Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature. 2009 Jan 8;457(7226):219-23.</reference_text>
      <pubmed_id>19129847</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson ER: Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11673-7.</reference_text>
      <pubmed_id>8265607</pubmed_id>
    </reference>
    <reference>
      <reference_text>Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995 Dec;80(12):3689-98.</reference_text>
      <pubmed_id>8530621</pubmed_id>
    </reference>
    <reference>
      <reference_text>Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER: Effect of testosterone and estradiol in a man with aromatase deficiency.  N Engl J Med. 1997 Jul 10;337(2):91-5.</reference_text>
      <pubmed_id>9211678</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK: DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.  Nature. 2008 Nov 6;456(7218):66-72.</reference_text>
      <pubmed_id>18987736</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Androstenedione</name>
        <accession>HMDB00053</accession>
      </metabolite>
      <reference>
        <reference_text>Paynter RA, Hankinson SE, Colditz GA, Kraft P, Hunter DJ, De Vivo I: CYP19 (aromatase) haplotypes and endometrial cancer risk.  Int J Cancer. 2005 Aug 20;116(2):267-74.</reference_text>
        <pubmed_id>15800924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testosterone</name>
        <accession>HMDB00234</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorotrianisene</name>
        <accession>HMDB14414</accession>
      </metabolite>
      <reference>
        <reference_text>Adashi EY, Hsueh AJ: Estrogens augment the stimulation of ovarian aromatase activity by follicle-stimulating hormone in cultured rat granulosa cells. J Biol Chem. 1982 Jun 10;257(11):6077-83.</reference_text>
        <pubmed_id>6804461</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etomidate</name>
        <accession>HMDB14437</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminoglutethimide</name>
        <accession>HMDB14501</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminoglutethimide</name>
        <accession>HMDB14501</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminoglutethimide</name>
        <accession>HMDB14501</accession>
      </metabolite>
      <reference>
        <reference_text>Greco F, Vicent MJ, Penning NA, Nicholson RI, Duncan R: HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines. J Drug Target. 2005 Sep-Nov;13(8-9):459-70.</reference_text>
        <pubmed_id>16332571</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminoglutethimide</name>
        <accession>HMDB14501</accession>
      </metabolite>
      <reference>
        <reference_text>Martinez-Campa C, Gonzalez A, Mediavilla MD, Alonso-Gonzalez C, Sanchez-Barcelo EJ, Cos S: Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 2005 Dec;94(3):249-54. Epub 2005 Oct 22.</reference_text>
        <pubmed_id>16244789</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminoglutethimide</name>
        <accession>HMDB14501</accession>
      </metabolite>
      <reference>
        <reference_text>Shirakawa H, Katsuki H, Kume T, Kaneko S, Akaike A: Aminoglutethimide prevents excitotoxic and ischemic injuries in cortical neurons.  Br J Pharmacol. 2006 Apr;147(7):729-36.</reference_text>
        <pubmed_id>16474421</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminoglutethimide</name>
        <accession>HMDB14501</accession>
      </metabolite>
      <reference>
        <reference_text>Siraki AG, Bonini MG, Jiang J, Ehrenshaft M, Mason RP: Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45. Epub 2007 Jun 30.</reference_text>
        <pubmed_id>17602675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminoglutethimide</name>
        <accession>HMDB14501</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefloquine</name>
        <accession>HMDB14502</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbimazole</name>
        <accession>HMDB14533</accession>
      </metabolite>
      <reference>
        <reference_text>Ayub M, Levell MJ: Structure-activity relationships of the inhibition of human placental aromatase by imidazole drugs including ketoconazole. J Steroid Biochem. 1988 Jul;31(1):65-72.</reference_text>
        <pubmed_id>3398530</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Betamethasone</name>
        <accession>HMDB14586</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorphenesin</name>
        <accession>HMDB14994</accession>
      </metabolite>
      <reference>
        <reference_text>Holloway AC, Stys KA, Foster WG: DDE-induced changes in aromatase activity in endometrial stromal cells in culture. Endocrine. 2005 Jun;27(1):45-50.</reference_text>
        <pubmed_id>16077170</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorphenesin</name>
        <accession>HMDB14994</accession>
      </metabolite>
      <reference>
        <reference_text>Younglai EV, Holloway AC, Lim GE, Foster WG: Synergistic effects between FSH and 1,1-dichloro-2,2-bis(P-chlorophenyl)ethylene (P,P'-DDE) on human granulosa cell aromatase activity. Hum Reprod. 2004 May;19(5):1089-93. Epub 2004 Apr 7.</reference_text>
        <pubmed_id>15070871</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terbinafine</name>
        <accession>HMDB14995</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Drostanolone</name>
        <accession>HMDB14996</accession>
      </metabolite>
      <reference>
        <reference_text>Navarro-Martin L, Blazquez M, Piferrer F: Masculinization of the European sea bass (Dicentrarchus labrax) by treatment with an androgen or aromatase inhibitor involves different gene expression and has distinct lasting effects on maturation. Gen Comp Endocrinol. 2009 Jan 1;160(1):3-11. Epub 2008 Oct 18.</reference_text>
        <pubmed_id>18983844</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testolactone</name>
        <accession>HMDB15031</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testolactone</name>
        <accession>HMDB15031</accession>
      </metabolite>
      <reference>
        <reference_text>Raman JD, Schlegel PN: Aromatase inhibitors for male infertility.  J Urol. 2002 Feb;167(2 Pt 1):624-9.</reference_text>
        <pubmed_id>11792932</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testolactone</name>
        <accession>HMDB15031</accession>
      </metabolite>
      <reference>
        <reference_text>Herzog AG, Klein P, Jacobs AR: Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism. Neurology. 1998 Mar;50(3):782-4.</reference_text>
        <pubmed_id>9521275</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testolactone</name>
        <accession>HMDB15031</accession>
      </metabolite>
      <reference>
        <reference_text>Dunkel L: Use of aromatase inhibitors to increase final height.  Mol Cell Endocrinol. 2006 Jul 25;254-255:207-16.</reference_text>
        <pubmed_id>16766117</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testolactone</name>
        <accession>HMDB15031</accession>
      </metabolite>
      <reference>
        <reference_text>Cepa MM, Tavares da Silva EJ, Correia-da-Silva G, Roleira FM, Teixeira NA: Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation. J Med Chem. 2005 Oct 6;48(20):6379-85.</reference_text>
        <pubmed_id>16190763</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edetic Acid</name>
        <accession>HMDB15109</accession>
      </metabolite>
      <reference>
        <reference_text>Moslemi S, Vibet A, Papadopoulos V, Camoin L, Silberzahn P, Gaillard JL: Purification and characterization of equine testicular cytochrome P-450 aromatase: comparison with the human enzyme. Comp Biochem Physiol B Biochem Mol Biol. 1997 Sep;118(1):217-27.</reference_text>
        <pubmed_id>9418012</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edetic Acid</name>
        <accession>HMDB15109</accession>
      </metabolite>
      <reference>
        <reference_text>Bellino FL, Holben L: Placental estrogen synthetase (aromatase): evidence for phosphatase-dependent inactivation. Biochem Biophys Res Commun. 1989 Jul 14;162(1):498-504.</reference_text>
        <pubmed_id>2546553</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edetic Acid</name>
        <accession>HMDB15109</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang F, Zhou D, Kao YC, Ye J, Chen S: Expression and purification of a recombinant form of human aromatase from Escherichia coli. Biochem Pharmacol. 2002 Nov 1;64(9):1317-24.</reference_text>
        <pubmed_id>12392814</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Edetic Acid</name>
        <accession>HMDB15109</accession>
      </metabolite>
      <reference>
        <reference_text>Milczarek R, Sokolowska E, Hallmann A, Kaletha K, Klimek J: NADPH- and iron-dependent lipid peroxidation inhibit aromatase activity in human placental microsomes. J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):230-5. Epub 2008 Apr 20.</reference_text>
        <pubmed_id>18499441</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nandrolone phenpropionate</name>
        <accession>HMDB15119</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Koutras A, Giannopoulou E, Kritikou I, Antonacopoulou A, Evans TR, Papavassiliou AG, Kalofonos H: Antiproliferative effect of exemestane in lung cancer cells.  Mol Cancer. 2009 Nov 24;8:109.</reference_text>
        <pubmed_id>19930708</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Robinson A: A review of the use of exemestane in early breast cancer.  Ther Clin Risk Manag. 2009 Feb;5(1):91-8. Epub 2009 Mar 26.</reference_text>
        <pubmed_id>19436613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Untch M, Jackisch C: Exemestane in early breast cancer: a review.  Ther Clin Risk Manag. 2008 Dec;4(6):1295-304.</reference_text>
        <pubmed_id>19337436</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Barnadas A, Gil M, Gonzalez S, Tusquets I, Munoz M, Arcusa A, Prieto L, Margeli-Vila M, Moreno A: Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer. 2009 Feb 10;100(3):442-9. Epub 2009 Jan 20.</reference_text>
        <pubmed_id>19156139</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Abrial C, Durando X, Mouret-Reynier MA, Thivat E, Bayet-Robert M, Nayl B, Dubray P, Pomel C, Chollet P, Penault-Llorca F: Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials. Int J Gen Med. 2009 Jul 30;2:129-40.</reference_text>
        <pubmed_id>20360896</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Nabholtz JM: Long-term safety of aromatase inhibitors in the treatment of breast cancer.  Ther Clin Risk Manag. 2008 Feb;4(1):189-204.</reference_text>
        <pubmed_id>18728707</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Brueggemeier RW: Update on the use of aromatase inhibitors in breast cancer.  Expert Opin Pharmacother. 2006 Oct;7(14):1919-30.</reference_text>
        <pubmed_id>17020418</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Brueggemeier RW, Hackett JC, Diaz-Cruz ES: Aromatase inhibitors in the treatment of breast cancer.  Endocr Rev. 2005 May;26(3):331-45. Epub 2005 Apr 6.</reference_text>
        <pubmed_id>15814851</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Letrozole</name>
        <accession>HMDB15141</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Letrozole</name>
        <accession>HMDB15141</accession>
      </metabolite>
      <reference>
        <reference_text>Ebert AD, Bartley J, David M, Schweppe KW: [Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis]. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.</reference_text>
        <pubmed_id>14505258</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Letrozole</name>
        <accession>HMDB15141</accession>
      </metabolite>
      <reference>
        <reference_text>Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM: Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst. 2004 Mar 17;96(6):456-65.</reference_text>
        <pubmed_id>15026471</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Letrozole</name>
        <accession>HMDB15141</accession>
      </metabolite>
      <reference>
        <reference_text>Murphy MJ Jr: Molecular Action and Clinical Relevance of Aromatase Inhibitors.  Oncologist. 1998;3(2):129-130.</reference_text>
        <pubmed_id>10388095</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Letrozole</name>
        <accession>HMDB15141</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tioconazole</name>
        <accession>HMDB15142</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Melatonin</name>
        <accession>HMDB01389</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miconazole</name>
        <accession>HMDB15242</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Econazole</name>
        <accession>HMDB15259</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Mauras N, Bishop K, Merinbaum D, Emeribe U, Agbo F, Lowe E: Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia. J Clin Endocrinol Metab. 2009 Aug;94(8):2975-8. Epub 2009 May 26.</reference_text>
        <pubmed_id>19470631</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Nabholtz JM: Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention. Oncology. 2006;70(1):1-12. Epub 2006 Jan 26.</reference_text>
        <pubmed_id>16439860</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rucklinger E, Samonigg H: Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11.</reference_text>
        <pubmed_id>18073378</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Cuzick J: Anastrozole.  Drugs Today (Barc). 2005 Apr;41(4):227-39.</reference_text>
        <pubmed_id>16034487</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Rugo HS: The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol. 2008 Jan;19(1):16-27. Epub 2007 Aug 9.</reference_text>
        <pubmed_id>17693420</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Milani M, Jha G, Potter DA: Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.  Clin Med Ther. 2009 Mar 31;1:141-156.</reference_text>
        <pubmed_id>19794821</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Gangadhara S, Bertelli G: Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women. Ther Clin Risk Manag. 2009 Aug;5(4):291-300. Epub 2009 May 4.</reference_text>
        <pubmed_id>19753124</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A: History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 2009 Jun;30(4):343-75. Epub 2009 Apr 23.</reference_text>
        <pubmed_id>19389994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levomethadyl Acetate</name>
        <accession>HMDB15358</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bifonazole</name>
        <accession>HMDB15583</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyproterone</name>
        <accession>HMDB15587</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Substance P</name>
        <accession>HMDB01897</accession>
      </metabolite>
      <reference>
        <reference_text>Gobbetti A, Zerani M, Di Fiore MM, Botte V: Relationships among GnRH, substance P, prostaglandins, sex steroids and aromatase activity in the brain of the male lizard Podarcis sicula sicula during reproduction. J Reprod Fertil. 1994 Aug;101(3):523-9.</reference_text>
        <pubmed_id>7525952</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfathiazole</name>
        <accession>HMDB15619</accession>
      </metabolite>
      <reference>
        <reference_text>Ji K, Choi K, Lee S, Park S, Khim JS, Jo EH, Choi K, Zhang X, Giesy JP: Effects of sulfathiazole, oxytetracycline and chlortetracycline on steroidogenesis in the human adrenocarcinoma (H295R) cell line and freshwater fish Oryzias latipes. J Hazard Mater. 2010 Oct 15;182(1-3):494-502. Epub 2010 Jun 19.</reference_text>
        <pubmed_id>20630653</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methyltestosterone</name>
        <accession>HMDB15655</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nandrolone decanoate</name>
        <accession>HMDB15694</accession>
      </metabolite>
      <reference>
        <reference_text>Takahashi K, Hallberg M, Magnusson K, Nyberg F, Watanabe Y, Langstrom B, Bergstrom M: Increase in [11C]vorozole binding to aromatase in the hypothalamus in rats treated with anabolic androgenic steroids. Neuroreport. 2007 Jan 22;18(2):171-4.</reference_text>
        <pubmed_id>17301684</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
